**To Stop or Not: Acute Pain Management in Patients Receiving Buprenorphine**

Brian Hazelrigg, PharmD

3.11.2020

1. Roberts AW, et al. Buprenorphine use and spending for opioid use disorder treatment trends from 2003 to 2015. Psychiatry Serv. 2018;69(7):832-835. doi:10.1176/appi.ps.201700315
2. Substance Abuse and Mental Health Services Administration. National Survey on Drug Use and Health. Available at [https://www.samhsa.gov/data/sites/defaulVfiles/cbhsq-reports/Ass1stant-Secretary­nsduh2018\_\_presentation.pdf](https://www.samhsa.gov/data/sites/defaulVfiles/cbhsq-reports/Ass1stant-Secretary%C2%ADnsduh2018__presentation.pdf)
3. Lexicomp. Buprenorphine. Wolters Kluwer Clinical Drug Information. 2020
4. Kuhlman JJ Jr, Lalani S, Magluilo J Jr, Levine B, Darwin WO. Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. J Anal Toxicol. 1996;20(6):369-78.
5. Grinnell SG, Ansonoff M, Marrone GF, et al. Mediation of buprenorphine analgesia by a combination of traditional and truncated mu opioid receptor splice variants. Synapse. 2016;70(10):395-407. doi:10.1002/syn.21914
6. Hlavaty A, Buprenorphine Induction in the Emergency Department for Opioid Use Disorder and Withdrawal
7. American Society of Anesthesiologists Task Force on Acute Pain M. Practice guidelines for acute pain management in the perioperative setting: an updated report by the American Society at Anesthesiologists Task Force on acute pain management. Anesthesiology. 2012;116(2):248-73.
8. Agency Medical Directors Guide, Dr. Bree Collaborative. Prescribing Opioids for Post-0peratille Pain -A Supplemental Guide. Available at: http//agencymedd1rectors.wa.gav/Files/FinalSupBreeAMDGPostopPain091318waNer.pdf